Brief: Maxcyte, Crispr Therapeutics Expand Clinical, Commercial Oncology License Agreement
09/11/2018 07:20
Nov 9 (Reuters) - CRISPR Therapeutics AG CRSP.O :
* MAXCYTE INC - CRISPR THERAPEUTICS AND MAXCYTE EXPAND
CLINICAL
AND COMMERCIAL LICENSE AGREEMENT INTO ONCOLOGY
* MAXCYTE INC - EXPANSION OF EXISTING RELATIONSHIP THAT WILL
ALLOW
CRISPR THERAPEUTICS TO DEPLOY MAXCYTE'S FLOW ELECTROPORATION
TECHNOLOGY
Source text for Eikon: ID:nRSI8499Ga
Further company coverage: CRSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics